Abstract:Polymer–drug conjugates (PDCs) have shown great promise in enhancing the efficacy and safety of cancer therapy. These conjugates combine the advantageous properties of both polymers and drugs, leading to improved pharmacokinetics, controlled drug release, and targeted delivery to tumor tissues. This review provides a comprehensive overview of recent developments in PDCs for cancer therapy. First, various types of polymers used in these conjugates are discussed, including synthetic polymers, such as poly(↋-caprolactone) (PCL), D-α-tocopheryl polyethylene glycol (TPGS), and polyethylene glycol (PEG), as well as natural polymers such as hyaluronic acid (HA). The choice of polymer is crucial to achieving desired properties, such as stability, biocompatibility, and controlled drug release. Subsequently, the strategies for conjugating drugs to polymers are explored, including covalent bonding, which enables a stable linkage between the polymer and the drug, ensuring controlled release and minimizing premature drug release. The use of polymers can extend the circulation time of the drug, facilitating enhanced accumulation within tumor tissues through the enhanced permeability and retention (EPR) effect. This, in turn, results in improved drug efficacy and reduced systemic toxicity. Moreover, the importance of tumor-targeting ligands in PDCs is highlighted. Various ligands, such as antibodies, peptides, aptamers, folic acid, herceptin, and HA, can be incorporated into conjugates to selectively deliver the drug to tumor cells, reducing off-target effects and improving therapeutic outcomes. In conclusion, PDCs have emerged as a versatile and effective approach to cancer therapy. Their ability to combine the advantages of polymers and drugs offers enhanced drug delivery, controlled release, and targeted treatment, thereby improving the overall efficacy and safety of cancer therapies. Further research and development in this field has great potential to advance personalized cancer treatment options.

Polypeptides–Drug Conjugates for Anticancer Therapy

Peptide-Drug Conjugates: A New Hope for Cancer Management

Recent Advances on Anticancer Protein/Peptide Delivery.

Recent Advances in Anti-cancer Protein/Peptide Delivery.

Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer

Drug conjugate-based anticancer therapy - Current status and perspectives

Polymeric Prodrug by Supramolecular Polymerization

Peptide-functionalized delivery vehicles for enhanced cancer therapy

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Advances in polymer-drug conjugated micelles in the delivery of anticancer drugs

Peptide Drug Conjugates and Their Role in Cancer Therapy

Cancer Nanomedicines Based on Synthetic Polypeptides.

Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy

Peptide-Mediated Nanocarriers for Targeted Drug Delivery: Developments and Strategies

Peptide-Drug Conjugate: A Novel Drug Design Approach

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic

Polypeptides-Based Nanocarriers in Tumor Therapy

Polysaccharide-Drug Conjugates: A Tool for Enhanced Cancer Therapy

Innovative Design of Targeted Nanoparticles: Polymer–Drug Conjugates for Enhanced Cancer Therapy

Peptides in Cancer Nanomedicine: Drug Carriers, Targeting Ligands and Protease Substrates.

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics